Prof. Gourinchas and his delegation toured Henlius’ formulation and cell culture laboratories. They engaged in extensive discussions with Ms. Xiaohui Guan, Vice Chairman of Fosun Pharma, and Dr. Jason Zhu, Executive Director, Chief Executive Officer and Chief Financial Officer of Henlius. The discussions focused on the company’s operational status, technological innovations, and global market expansion.

Driven by technology innovation and committed to offering high-quality, affordable and innovative biologic medicines to patients worldwide, Henlius collaborates with its global business partners to continuously bring affordable, high-quality biologics to patients worldwide. Henlius' self-developed and -manufactured trastuzumab biosimilar HANQUYOU (trade name: HERCESSI™ in the U.S. and Zercepac^® in Europe) has been approved in over 40 countries, including China, the United States, the United Kingdom, Switzerland, Australia, Saudi Arabia, and Brazil, covering Asia, Europe, Latin America, and Oceania. Additionally, Henlius' self-developed and -manufactured innovative product HANSIZHUANG, an anti-PD-1 monoclonal antibody (mAb), and rituximab biosimilar HANLIKANG, have received approvals in Indonesia and Peru, respectively. To date, the company's five marketed products have benefited over 600,000 patients.

Moving forward, Henlius will continue to strive for technological innovation and global collaboration, accelerating the provision of affordable, high-quality biologics for patients worldwide.”